Investigational drug · Phase 3
HDM1005
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obstructive Sleep Apnea (OSA) and Obesity, Obesity, Type 2 Diabetes.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
13
Any phase or sponsor naming "HDM1005"
First trial start
2025
Feb 7, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HDM1005", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obstructive Sleep Apnea (OSA) and Obesity
- Obesity
- Type 2 Diabetes
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HDM1005" as an intervention, largest first.
- A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorPivotal-lookingNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07417306 · 912 participants (planned) · Start Mar 27, 2026 · Primary completion Aug 30, 2027
Drug: HDM1005 1; HDM1005 2 and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
- Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without DiabetesPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07279194 · 825 participants (planned) · Start Oct 14, 2025 · Primary completion Sep 20, 2026
Drug: HDM1005 1; HDM1005 2 and 1 more · For: Obesity & Overweight
Sites: Shanghai, China
- Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without DiabetesPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07521631 · 372 participants (planned) · Start Mar 31, 2026 · Primary completion Feb 4, 2027
Drug: HDM1005 dose level 1; HDM1005 dose level 2 and 2 more · For: Obesity
Sites: Shanghai, China
- A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise AlonePivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07394114 · 240 participants (planned) · Start Feb 24, 2026 · Primary completion Aug 28, 2027
Drug: HDM1005 1; HDM1005 2 and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
- Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes MellitusPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06886126 · 240 participants (planned) · Start Feb 7, 2025 · Primary completion Sep 23, 2025
Drug: HDM1005 injection or placebo · For: Obesity
Sites: Nanjing, China
- A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminPivotal-lookingRecruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07109700 · 216 participants (planned) · Start Apr 30, 2025 · Primary completion Jan 31, 2026
Drug: HDM1005 1; HDM1005 2 and 4 more · For: Type 2 Diabetes
Sites: Beijing, China
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) TherapyPivotal-lookingNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07787260 · 200 participants (planned) · Start Aug 2026 · Primary completion Mar 2028
Drug: HDM1005; Placebo · For: Obstructive Sleep Apnea (OSA) and Obesity
Sites: Beijing, China
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) TherapyPivotal-lookingNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07794397 · 200 participants (planned) · Start Sep 2026 · Primary completion Sep 2028
Drug: HDM1005; Placebo · For: Obstructive Sleep Apnea (OSA) and Obesity
Sites: Beijing, China
- A Pharmacokinetic Study of HDM1005 Injection at Different Injection SitesPivotal-lookingActive, not recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07828197 · 135 participants (planned) · Start Sep 3, 2026 · Primary completion Oct 2026
Drug: HDM1005 · For: Overweight and/or Obesity; Healthy Participants
Sites: Hefei, China
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT06637020 · 80 participants · Start Jun 21, 2024 · Primary completion Mar 28, 2025
Drug: HDM1005 injection or placebo; HDM1005 injection or placebo · For: Overweight and Obesity
Sites: Hefei, China
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of a High-Potency Balanced GLP-1/GIP Dual Agonist by Molecular Dynamics Evolution.
Zhang N, Teng L, Yu X, et al. · J Med Chem 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.